A treat-to-target strategy versus symptom-driven management of gout in the Netherlands (GO TEST Overture): a multicentre, open-label, pragmatic, superiority, randomised controlled trial - PubMed
6 hours ago
- #randomized-controlled-trial
- #gout
- #treat-to-target
- The study compared a treat-to-target strategy with symptom-driven management for gout in the Netherlands.
- A treat-to-target approach aimed for a serum urate concentration of less than 0.36 mmol/L, while symptom-driven management did not set a specific target.
- The trial involved 308 participants, predominantly male (87%), with a mean age of 65.93 years.
- Remission rates were higher in the treat-to-target group (39.4%) compared to the symptom-driven group (24.0%).
- Adverse events were slightly lower in the treat-to-target group (42%) versus the symptom-driven group (53%).
- No serious drug-related adverse events or treatment-related deaths were reported.
- The findings support the use of serum urate-guided therapy for better long-term gout management.